GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 103 filers reported holding GRITSTONE ONCOLOGY INC in Q2 2021. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,960 | -11.8% | 18,000 | 0.0% | 0.00% | – |
| Q2 2023 | $35,100 | -79.8% | 18,000 | -57.3% | 0.00% | – |
| Q1 2022 | $174,000 | -67.8% | 42,200 | +0.2% | 0.00% | – |
| Q4 2021 | $541,000 | +52.0% | 42,100 | +27.6% | 0.00% | – |
| Q3 2021 | $356,000 | +18.3% | 33,000 | 0.0% | 0.00% | – |
| Q2 2021 | $301,000 | +30.9% | 33,000 | +35.2% | 0.00% | – |
| Q1 2021 | $230,000 | +42.9% | 24,400 | -40.2% | 0.00% | – |
| Q4 2020 | $161,000 | +49.1% | 40,800 | 0.0% | 0.00% | – |
| Q3 2020 | $108,000 | -63.6% | 40,800 | -8.9% | 0.00% | – |
| Q2 2020 | $297,000 | +92.9% | 44,800 | +69.7% | 0.00% | – |
| Q1 2020 | $154,000 | -7.8% | 26,400 | +41.9% | 0.00% | – |
| Q4 2019 | $167,000 | +3.7% | 18,600 | 0.0% | 0.00% | – |
| Q3 2019 | $161,000 | +10.3% | 18,600 | +42.0% | 0.00% | – |
| Q2 2019 | $146,000 | -48.8% | 13,100 | -34.5% | 0.00% | – |
| Q3 2018 | $285,000 | – | 20,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |